Dec. 1 - Regeneron, UPenn's plan to turn a COVID-19 drug into a nasal spray | New data pave path for a once-hot biotech

Regeneron, UPenn to use gene therapy tools to deliver a COVID-19 antibody drug; A closer look at the behind-the-scenes companies moving coronavirus vaccines around the world View online | Signup | Forward

Daily Dive Dec.​ 1,​ 2020 | Today's news and insights for biopharma leaders   BROUGHT TO YOU BY — Koneksa Health Koneksa: The Digital Biomarker Company Koneksa is changing effect detection and revolutionizing clinical research strategies. And we're doing it with digital biomarkers. Meet Koneksa.   With anemia data, Agios blood disease drug takes a crucial step forward Phase 3 results announced Tuesday boost chances that Agios' drug might not just win approval for a rare type of anemia, but also be useful in treating other blood diseases. Regeneron, UPenn to use gene therapy tools to deliver a COVID-19 antibody drug Working with University of Pennsylvania researcher Jim Wilson, Regeneron aims to develop a nasal spray version of the coronavirus treatment recently cleared by the Food and Drug Administration.  Sponsored Content by MilliporeSigma BPOG extractables data in single-use systems adoption Whitepaper: The role of biophorum extractables data in the effective adoption of single-use systems. Download now. Deep Dive A closer look at the behind-the-scenes companies moving coronavirus vaccines around the world Freight forwarders, the linchpins of the supply chain, face the daunting task of ensuring hundreds of millions of doses make the journey from factory to clinic. Read more news Featured Resources FROM: SGS Latest Webinars and Whitepapers [Webinar] Understanding Molecules: Choosing the Right Method for Characterizing Biologics [Whitepaper] Advancing the Detection of E&L By Pharma Manufacturers [Whitepaper] Nitrosamine Testing: The Regulatory Aspects From Our Library Trendline Inside the Rapidly Changing World of Gene Therapy Trendline What You Need to Know About Oncology's Research Boom Webinar - on demand Transforming the Pharma Supply Chain with Blockchain By studioID View all resources What We're Reading Associated Press First blood test to help diagnose Alzheimer's goes on sale Axios FDA chief called to West Wing Nature DeepMind's AI makes gigantic leap in solving protein structures Reuters AstraZeneca sells former blockbuster cholesterol drug for $320 million Suggest a story we should read Upcoming Events Accelerating Targeted Therapies: Defining the Signaling Pathways of Each Single Cell Dec. 2, 2020 - Dec. 2, 2020 | Webinar 2pm ET Advancing Single-Use Solutions for End-To-End Purity and Reliability Dec. 8, 2020 - Dec. 8, 2020 | Webinar 11am ET Taking the First Step Toward a Critical Evolution of Pharma’s Commercial Model Dec. 9, 2020 - Dec. 9, 2020 | Webinar 11am ET Company Announcements Press releases from companies in your industry. Camargo client Incannex Healthcare seeks expedited pre-IND meeting, Emergency Use Authorization for anti-inflammatory COVID-19 treatment Press release from Camargo Pharmaceutical Services Vivera Pharmaceuticals Announces $440 Million in Backing by JR Dallas Wealth Management Press release from Vivera Pharmaceuticals Post a press release Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc.. 1575​ Eye St NW, 4th Floor, Washington,​ DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip